Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor wi... Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. 詳細を表示
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.04 | -36.4912280702 | 2.85 | 3.3 | 1.59 | 14365833 | 2.33150654 | CS |
4 | -0.78 | -30.1158301158 | 2.59 | 3.3 | 1.38 | 3692577 | 2.31572436 | CS |
12 | -1.56 | -46.2908011869 | 3.37 | 4.318 | 1.38 | 1309632 | 2.35313223 | CS |
26 | -2.84 | -61.0752688172 | 4.65 | 5.15 | 1.38 | 651254 | 2.43518783 | CS |
52 | -6.7835 | -78.9375690929 | 8.5935 | 22.35 | 1.38 | 1282081 | 8.87224743 | CS |
156 | -1385.69 | -99.8695495495 | 1387.5 | 1402.425 | 1.38 | 1922679 | 128.83279395 | CS |
260 | -6748.19 | -99.9731851852 | 6750 | 8182.5 | 1.38 | 1708889 | 334.72975294 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約